Hansa Biopharma — Januar 2022
-
Hansa Biopharma AB: Hansa Biopharma ingår avtal med AskBio för att utvärdera imlifidas som förbehandling till genterapi vid Pompes sjukdom
-
Hansa will receive $5M and AskBio will have an exclusive option to enter a development and commercialization agreement following the evaluation of a phase I/II study.
AskBio will be responsible for conducting pre-clinical and clinical studies with imlifidase, while Hansa will supply its materials.
Pompe disease is a rare genetic metabolic disorder that occurs in 1 in every 40K births. -
Super nyhed, god start på året (-:
-
-
Lad os håbe at MSE stopper deres “julelege” i Hansa, med skiftevis at køre kursen op og ned efter behag.
Vi får se, jeg tvivler 
men håber -
Jeg tvivler desværre på, at den her aftale er nok til at lø
fte Hansa Biopharma for alvor. Jeg tror der skal en aftale til med væsentlig bedre milestone's og upfront betaling. Eller klare indikationer på at Imlifidasesalget i Europa begynder at accelererer. Når det er sagt, er jeg selv aktionær i Hans, og har god tro på, at virksomheden kommer til at skabe værdi. -
Hansa Biopharma: Business update and certain key financials https://www.proinvestor.com/index.php?p=debat_1&postid=99977
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind